179 related articles for article (PubMed ID: 16777663)
1. Bioactive lipids in schizophrenia.
Berger GE; Smesny S; Amminger GP
Int Rev Psychiatry; 2006 Apr; 18(2):85-98. PubMed ID: 16777663
[TBL] [Abstract][Full Text] [Related]
2. The role of phospholipases A2 in schizophrenia.
Law MH; Cotton RG; Berger GE
Mol Psychiatry; 2006 Jun; 11(6):547-56. PubMed ID: 16585943
[TBL] [Abstract][Full Text] [Related]
3. Implications of lipid biology for the pathogenesis of schizophrenia.
Berger GE; Wood SJ; Pantelis C; Velakoulis D; Wellard RM; McGorry PD
Aust N Z J Psychiatry; 2002 Jun; 36(3):355-66. PubMed ID: 12060184
[TBL] [Abstract][Full Text] [Related]
4. The membrane hypothesis of schizophrenia.
Horrobin DF; Glen AI; Vaddadi K
Schizophr Res; 1994 Oct; 13(3):195-207. PubMed ID: 7841132
[TBL] [Abstract][Full Text] [Related]
5. Extending David Horrobin's membrane phospholipid theory of schizophrenia: overactivity of cytosolic phospholipase A(2) in the brain is caused by overdrive of coupled serotonergic 5HT(2A/2C) receptors in response to stress.
Eggers AE
Med Hypotheses; 2012 Dec; 79(6):740-3. PubMed ID: 22986004
[TBL] [Abstract][Full Text] [Related]
6. Response to 'signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia'.
Christie AC
Aust N Z J Psychiatry; 2001 Jun; 35(3):386-8. PubMed ID: 11437816
[No Abstract] [Full Text] [Related]
7. [Accelerated breakdown of membrane phospholipids in schizophrenia--implications for the hypofrontality hypothesis].
Gattaz WF; Brunner J; Schmitt A; Maras A
Fortschr Neurol Psychiatr; 1994 Dec; 62(12):489-96. PubMed ID: 7835820
[TBL] [Abstract][Full Text] [Related]
8. [Schizophrenia and neural transmission: an excess of analogical treatment?].
Tassin JP
Encephale; 1996 Oct; 22 Spec No 3():91-8. PubMed ID: 9036015
[No Abstract] [Full Text] [Related]
9. Phospholipid membrane abnormalities and reduced niacin skin flush response in schizophrenia.
Buretić-Tomljanović A; Giacometti J; Nadalin S; Rubesa G; Vulin M; Tomljanović D
Psychiatr Danub; 2008 Sep; 20(3):372-83. PubMed ID: 18827766
[TBL] [Abstract][Full Text] [Related]
10. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression.
Bazan NG; Rodriguez de Turco EB; Allan G
J Neurotrauma; 1995 Oct; 12(5):791-814. PubMed ID: 8594208
[TBL] [Abstract][Full Text] [Related]
11. Ca(2+)-independent fusion of synaptic vesicles with phospholipase A2-treated presynaptic membranes in vitro.
Nishio H; Takeuchi T; Hata F; Yagasaki O
Biochem J; 1996 Sep; 318 ( Pt 3)(Pt 3):981-7. PubMed ID: 8836147
[TBL] [Abstract][Full Text] [Related]
12. Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness?
Hibbeln JR; Palmer JW; Davis JM
Biol Psychiatry; 1989 Apr; 25(7):945-61. PubMed ID: 2566335
[TBL] [Abstract][Full Text] [Related]
13. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results.
Peet M
Prostaglandins Leukot Essent Fatty Acids; 2003 Dec; 69(6):477-85. PubMed ID: 14623502
[TBL] [Abstract][Full Text] [Related]
14. Role of intracellular calcium and phospholipase A2 in arachidonic acid-induced toxicity in liver cells overexpressing CYP2E1.
Caro AA; Cederbaum AI
Arch Biochem Biophys; 2007 Jan; 457(2):252-63. PubMed ID: 17118330
[TBL] [Abstract][Full Text] [Related]
15. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
[TBL] [Abstract][Full Text] [Related]
16. Roles for nitric oxide and arachidonic acid in the induction of heterosynaptic cerebellar LTD.
Reynolds T; Hartell NA
Neuroreport; 2001 Jan; 12(1):133-6. PubMed ID: 11201073
[TBL] [Abstract][Full Text] [Related]
17. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics.
Khan MM; Evans DR; Gunna V; Scheffer RE; Parikh VV; Mahadik SP
Schizophr Res; 2002 Nov; 58(1):1-10. PubMed ID: 12363384
[TBL] [Abstract][Full Text] [Related]
18. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications.
Mahadik SP; Evans DR
Psychiatr Clin North Am; 2003 Mar; 26(1):85-102. PubMed ID: 12683261
[TBL] [Abstract][Full Text] [Related]
19. Proton and 31-phosphorus neurospectroscopy in the study of membrane phospholipids and fatty acid intervention in schizophrenia, depression, chronic fatigue syndrome (myalgic encephalomyelitis) and dyslexia.
Puri BK
Int Rev Psychiatry; 2006 Apr; 18(2):145-7. PubMed ID: 16777668
[TBL] [Abstract][Full Text] [Related]
20. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia.
Mahadik SP; Pillai A; Joshi S; Foster A
Int Rev Psychiatry; 2006 Apr; 18(2):119-31. PubMed ID: 16777666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
